Results 171 to 180 of about 7,855 (224)
Some of the next articles are maybe not open access.
Edaravone for acute ischaemic stroke
Cochrane Database of Systematic Reviews, 2011Neuroprotection is a promising therapeutic strategy for the treatment of acute ischaemic stroke. Edaravone is a neuroprotective agent that has been widely used in China, and several studies have suggested that it may be beneficial in acute ischaemic stroke.To assess the efficacy and safety of edaravone for acute ischaemic stroke.We searched the ...
Feng, Shejun +7 more
openaire +3 more sources
Experimental Neurology, 2009
0014-4886/$ – see front matter © 2009 Elsevier Inc. Al doi:10.1016/j.expneurol.2009.03.001 ⁎ Fax: +81 75 761 9780. E-mail address: ryosuket@kuhp.kyoto-u.ac.jp. Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive and relatively selective degeneration of upper and lower motor neurons.
openaire +2 more sources
0014-4886/$ – see front matter © 2009 Elsevier Inc. Al doi:10.1016/j.expneurol.2009.03.001 ⁎ Fax: +81 75 761 9780. E-mail address: ryosuket@kuhp.kyoto-u.ac.jp. Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive and relatively selective degeneration of upper and lower motor neurons.
openaire +2 more sources
Edaravone for acute intracerebral haemorrhage
Cochrane Database of Systematic Reviews, 2009Intracerebral haemorrhage (ICH) causes significant morbidity and mortality. Prognosis for ICH patients is poor. Edaravone may be safe and effective in reducing the risk of early death and improving long-term functional outcomes in survivors.To assess the safety and efficacy of edaravone for acute ICH.We searched the Cochrane Stroke Group Trials ...
Jie, Yang +5 more
openaire +2 more sources
Edaravone Oral Suspension (Radicava)
Canadian Journal of Health Technologies, 2023CADTH recommends that Radicava should be reimbursed by public drug plans for the treatment of patients with amyotrophic lateral sclerosis (ALS), if certain conditions are met. Radicava oral suspension should only be covered to treat patients with ALS provided that it is covered for a similar patient population and in a similar way to the ...
openaire +1 more source
Edaravone prevents kainic acid-induced neuronal death
Brain Research, 2008There is growing evidence that free radical generation may play a key role in the neuronal damage induced by prolonged convulsions. Free radical scavengers are known to inhibit neuronal death induced by exposure to excitotoxins. However, this neuroprotective effect has not been demonstrated with treatment after seizures had been stopped.
Ryohei, Miyamoto +4 more
openaire +2 more sources
Edaravone administration in pivotal clinical Study 19
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019Recently, ALSFTD published an editorial entitled “Is edaravone harmful? (A placebo is not a control)” (1).
Angela, Genge, Benjamin, Brooks
openaire +2 more sources
Edaravone suppresses degradation of type II collagen
Biochemical and Biophysical Research Communications, 2016Osteoarthritis (OA) is a degenerative joint disease affecting millions of people. The degradation and loss of type II collagen induced by proinflammatory cytokines secreted by chondrocytes, such as factor-α (TNF-α) is an important pathological mechanism to the progression of OA.
Chen, Huang +4 more
openaire +2 more sources
Protective effect of edaravone against endolymphatic hydrops
Acta Oto-Laryngologica, 2007Our findings suggest that edaravone prevented the production of reactive oxygen species (ROS). Edaravone also delayed the formation of endolymphatic hydrops in guinea pigs, but had no effect on endolymphatic hydrops.To analyse the protective effect of a free radical scavenger, edaravone, on endolymphatic hydrops.Guinea pigs were subjected to surgical ...
Masaya, Takumida +5 more
openaire +2 more sources